This contradicts another school of thought where the Fas/FasL receptor interaction grant the tumor cell an immune-privileged status, supported by studies demonstrating that the FasL expression in cancer cells deliver death signals to activated Fas-positive T lymphocytes [13-15]. The gene discussed is FAS; the disease is neoplasm.